Company profile ARCT

Arcturus Therapeutics Holdings Inc
founded in 2013 and based in san diego, calif., arcturus therapeutics is poised to become an industry leader in the application of rnai technologies for the treatment of disease and improved quality of life. the company’s aim is to develop breakthrough technology and novel therapeutics for rare diseases for which there is no adequate treatment. backed by a management team wit...h extensive experience in the discovery and development of therapeutic modalities, arcturus is on the forefront of research and development of nanoparticle sirna drug delivery systems. Show More
Quarter analysis & expected interestLast update: February 08 2024 15:11:40.

After 39 days of this quarter the interest is at 49.0. Based on that we can calculate that during remaining 52 days it will total up to 114.0.
That appears to be equal to previous quarter and same quarter last year.

YearQ1Q2Q3Q4
201944
96
118.2% QoQ
47
-51.0% QoQ
38
-19.1% QoQ
2020 140
218.2% YoY 268.4% QoQ
349
263.5% YoY 149.3% QoQ
269
472.3% YoY -22.9% QoQ
315
728.9% YoY 17.1% QoQ
2021 198
41.4% YoY -37.1% QoQ
115
-67.0% YoY -41.9% QoQ
129
-52.0% YoY 12.2% QoQ
130
-58.7% YoY 0.8% QoQ
2022 77
-61.1% YoY -40.8% QoQ
150
30.4% YoY 94.8% QoQ
117
-9.3% YoY -22.0% QoQ
107
-17.7% YoY -8.5% QoQ
2023 111
44.2% YoY 3.7% QoQ
157
4.7% YoY 41.4% QoQ
182
55.6% YoY 15.9% QoQ
135
26.2% YoY -25.8% QoQ
2024 49
-55.9% YoY -63.7% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Arcturus Therapeutics -stock -company search interestLast update: February 08 2024 15:11:39.
Correlation coefficient between keyword and revenue is -0.19
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 15:11:42.

The average 5 years interest of Arcturus Therapeutics -stock -company was 11.32 per week.
The last year interest of Arcturus Therapeutics -stock -company compared to the last 5 years has changed by 2.74%.
This is something to be checked.
The last year interest is quite higher compared to 5 years ago. It has increased by 132.6%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for ARCT
Earnings date: 2024-02-26 After close
Company name: Arcturus Therapeutics Holdings Inc
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-05-07T20:01:00Z

BusinessWire
Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress

2026-04-27T20:01:00Z

BusinessWire
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026

2026-04-24T16:05:10-04:00

SEC
DEF 14A Form - Other definitive proxy statements - Arcturus Therapeutics Holdings Inc. (0001768224) (Filer)

2026-04-20T12:30:00Z

GlobeNewswire
When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech

2026-03-20T13:01:59Z

Analyst Upgrades
This Rubrik Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday

2026-03-20T11:48:31Z

Analyst Upgrades
This BP Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Friday

2026-03-19T13:14:03Z

Analyst Upgrades
This Rocket Lab Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

2026-03-19T13:05:16Z

Analyst Upgrades
This Union Pacific Analyst Turns Bullish; Here Are Top 3 Upgrades For Wednesday

2026-03-18T12:00:38Z

Analyst Upgrades
This Evommune Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

2026-03-18T10:45:59Z

Analyst Upgrades
B. Riley Securities Initiates Coverage On Arcturus Therapeutics with Buy Rating, Announces Price Target of $22

2026-03-05T20:25:47Z

Analyst Upgrades
Citigroup Maintains Buy on Arcturus Therapeutics, Lowers Price Target to $21

2026-03-05T14:00:00Z

BusinessWire
Arcturus Therapeutics to Attend Upcoming Investor Conference

2026-03-04T18:12:47Z

Analyst Upgrades
Citigroup Maintains Neutral on Arcturus Therapeutics, Raises Price Target to $8

2026-03-04T13:47:44Z

Analyst Upgrades
Piper Sandler Maintains Overweight on Arcturus Therapeutics, Lowers Price Target to $25

2026-03-03T21:01:00Z

BusinessWire
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress